Lenalidomide triggers T-cell proliferation in vivo in first-line and R/R patients with FL. (A) List of canonical pathways related to cell cycle and DNA replication upregulated in PD-1⁺ T cells. (B) Ki-67 expression by circulating CD4 and CD8 memory T cells in first-line (upper row) or R/R patients with FL (lower row) measured by flow cytometry at the indicated time points. D0, first day of the first cycle of treatment (before lenalidomide intake); D7, seventh day of the first cycle (before obinutuzumab infusion); D28, first day of the second cycle (before lenalidomide intake); end, end of induction. Median values are depicted as red lines. ***P < .001, multiple paired samples Wilcoxon tests. FDR, false discovery rate; .q.val, q-value.